Printer Friendly

Cryptococcus neoformans infection among human immunodeficiency virus patients on highly active antiretroviral therapy in Benin City, Nigeria.

INTRODUCTION

Infection with the pathogenic yeast Cryptoccocus neoformans is a well-recognized complication of immunosuppression (1). C. neoformans meningitis occurs in 30%-50% of human immunodeficiency virus (HIV) infected individuals in sub-Saharan Africa and the developing world (2). A recent analysis estimated that each year there are >900,000 cases of and 600,000 deaths due to cryptoccocal meningitis globally, with most cases occurring in sub-Saharan Africa (2).

Cryptococcal meningitis is a common opportunistic infection and AIDS-defining illness in patients with late stage HIV infection, particularly in Southeast Asia and Southern and East Africa. Cryptococcal meningitis also occurs in patients with other forms of immunosuppression and in apparently immunocompetent individuals. In parts of sub-Sahara Africa with the highest HIV prevalence, cryptococcal meningitis is now the leading cause of community-acquired meningitis ahead of Streptococcus pneumoniae and Neisseria meningitis (3).

In HIV infected patients, cryptococcosis is associated with CD4 counts of <200 cell/[micro]L (2,3). In the highly active antiretroviral therapy (HAART) era, the prevalence of C. neoformans infection had been reported to decrease (4). To our knowledge, there is no report on C. neoformans infection in our Institution and records of cerebrospinal fluid among non-HIV individuals in the last 5 years has not reported C. neoformans as being the cause of meningitis. Although HAART has been reported to decrease the prevalence of C. neoformans infections, it carries the additional burden of immune-reconstitution inflammatory syndrome in patients with C. neoformans infections (4). To our knowledge there are no reports of C. neoformans infections among HIV patients, especially those on HAART. Therefore, we determined the prevalence of C. neoformans infections among HIV patients on HAART, as well as the effect of age, gender and CD4 count on this prevalence.

MATERIALS AND METHODS

Study area

This study was carried out between 1st February 2010 to 31st January 2011, at the University of Benin Teaching Hospital. The hospital is a tertiary hospital with a referral status and centre for the United States President's Emergency Plan for AIDS Relief (PEPFAR) and Institute of Human Virology, Nigeria (IHVN) HIV/ AIDS intervention. The intervention involves free HIV screening, treatment and management of HIV patients.

Study population

A total of 333 HIV patients on HAART for 3-6 months were recruited for this study. The age range of the patients was 21-60 years and consists of 156 males and 177 females. The HAART regimen included zidovudine, nevirapine and stavudine. All patients had signs and symptoms of C. neoformans infections such as fever, headache, photophobia, phonophobia, cough, and altered mental status including personality changes. Informed consent was obtained from all patients prior to specimen collection. The Ethical Committee of the University of Benin Teaching Hospital approved the protocol for this study.

CD4 and cryptococcal capsular antigen testing

Ten ml of blood was aseptically collected from each patient and dispensed into ethylenediamine tetracetic acid (EDTA) and plain vacutainers. The EDTA sample was used to determine CD4 cell counts by flow cytometry (Partec, Germany) following the manufacturer's instruction. Briefly, 20 [micro]l of whole blood was placed in a Partec tube, and 20 [micro]l of CD4+ T cell monoclonal antibodies was added. The mixture was then incubated in the dark for 15 minutes at room temperature after which 800 [micro]l of buffer was added. The tube was then placed in the flow cytometer for counting and the CD4+ T cells value obtained from a programmed computer connected to the instrument.

Sera obtained from the clotted samples in plain containers were used to detect cryptococcal capsular antigen using the latex-cryptococcus antigen detection system (Immuno-Mycologic, Inc, Norman, USA) following the manufacturer's instructions.

Statistical analysis

The data were analyzed with Chi square ([X.sup.2]) or Fisher's exact test and odds ratio analysis using the statistical software, INSTAT[R] (GraphPad Software Inc., La Jolla, CA, USA).

RESULTS

The prevalence of cryptococcal infection was higher in females (11.3%) than in males (8.33%), Although female gender appeared to be a risk factor for cryptococcal infection, this failed to reach statistical significance (Table 1). The prevalence of cryptococcal infection decreased with age from 14.04% in the 21-30 years age group to 6.90% in the 41-50 years age group, rising slightly to 7.02% in the 51-60 years age group. Age did not significantly affect the prevalence of cryptococcosis. Patients with CD4 cell counts of < 200 cell/[micro]L had a significantly higher prevalence of cryptococcal infection than those with CD4 cell counts of [greater than or equal to] 200 cell/[micro]l, and CD4 counts of < 200 cell/[micro]L was associated with cryptococcal infections among HIV patients on HAART (Table 1).

DISCUSSION

The incidence of infections caused by the encapsulated yeast C. neoformans has risen markedly over the past 20 years as a result of the HIV epidemic and increasing use of immunosuppressive therapies (3). Although incidence and mortality have decreased in the era of HAART, cryptococcal meningitis remains an important cause of mobility and mortality in the AIDS population especially in the developing world (4).

An overall prevalence of 9.91% of cryptococcal infection among HIV patients on HAART was observed in this study. This is higher than 3.2% observed among HIV patients from sub-Sahara Africa (5). This is the first report of HIV-associated cryptococcosis in our Institution and perhaps in Nigeria. It has been reported that in countries with a large access to antiretroviral therapy, overall mortality and incidence of AIDS-defining opportunistic infections have been reduced dramatically (6), and indeed a 46% reduction in cyptococcosis in the HAART era was reported in France (7). The prevalence of 9.9% observed in this study is, however, lower than a prevalence of 30% in individuals of African origin in France (7). Although being of African origin has been reported to be associated with an increased risk of cryptococcosis in the HAART era (7), geographical location and time of analysis may play a more important role on the prevalence of cryptococcosis among HIV patients as the prevalence obtained in our study was lower than previously reported (2).

Age and gender did not significantly affect the prevalence of cryptococcosis among HIV patients on HAART. Older age (35-45 years) was reported to associated with cryptococcosis among HIV patients on HAART (7). This was not observed in our study. However, CD4 counts of < 200 cells/[micro]L was significantly associated with cryptococcosis. This agrees with previous reports (1,2). It is important to note that those studies (1,2) did not state whether their patients were on HAART. HAART has been reported to improved CD4 counts (8).However, patients on HAART that still have low CD4 counts (< 200 cell/[micro]L) are at an increased risk of developing opportunistic infections and in our study C. neoformans infections.

It has been reported that some of the antiretrovirals used in the HAART regime interact with antifungal agents used to treat cryptococcosis and HIV patients with cryptococcal meningitis who initiate antiretroviral therapy are at particularly high risk for the immuno-reconstitution inflammatory syndrome (IRIS) (4). Physicians should bear these in mind as they manage cryptococcal infections in HIV patients and indeed some have suggested that HAART should be initiated 2-6 weeks after commencement of antifungal therapy in an effort to reduce the occurrence of IRIS (4).

Our study underscores the importance of cryptococcal infections among HIV patients on HAART where an overall prevalence of 9.9% was observed and HIV patients on HAART with CD4 counts of < 200 cells/[micro]L had a 2 to 9 fold increased risk of developing cryptococcal infections.

AUTHOR INFORMATION

Christopher A Egbe, MPhil MSc AMLSCN, Senior Medical Laboratory Scientist [1]

Richard Omoregie, MPhil MSc FMLSCN, Lecturer [1,2]

Otibhor Alex-Ighodalo, BMLS AMLSC, Senior Medical Laboratory Scientist [3]

[1] Department of Medical Microbiology, [2] School of Medical Laboratory Sciences, and [3] Department of Haematology, University of Benin Teaching Hospital, Benin City, Edo State, Nigeria.

Author for correspondence: Christopher Egbe. Email: egbeaye@yahoo.com

REFERENCES

(1.) French N, Gray K, Watera C, Nakiyingi J, Lugada E, Moore M, et al. Cryptococcal infection in a cohort of HIV-1--infected Ugandan adults. AIDS 2002; 16: 1031-1038.

(2.) Subramaniam K, Metzger B, Hanau LH, Guh A, Rucker L, Badri S, et al. 1gM(+) memory B cell expression predicts HIV-associated cryptococcosis status. J Infect Dis 2009; 200: 244-251.

(3.) Bicanic T, Harrison TS. Cryptococcal meningitis. Br Med Bull 2005; 72: 99-118.

(4.) Warkentien T, Crum-Cianflone NF. An update on Cryptococcosis among HIV-infected patients. Int J STD AIDS 2010; 21: 679-684.

(5.) Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptoccocal meningitis among persons living with HIV/AIDS. AIDS 2009; 23: 525-530.

(6.) Lortholary O, Poizat G, Zeller V, Neuville, S, Boibieaux A, Alvarez M, et al. Long term outcome of AIDS associated cryptococcosis in the era of combination antiretroviral therapy AIDS 2006; 20: 2183-2191.

(7.) Dromer F, Mathoulin-Pelissier S, Frontanet A, Ronin O, Dupont B, Lortholary O; French Cryptococcus Study Group. Epidemiology of HIV-associated cryptococcosis in France (1985-2001): comparison of the pre- and post-HAART eras. AIDS 2004; 18; 555-562.

(8.) Odunukwe, N., Idigbe, O., Kanki, P,; Adewole, T., Onwujekwe, D., Audu, R. et al. Haematological and biochemical response to treatment of HIV-1 infection with a combination of nevirapine + stavudine + lamivudine in Lagos, Nigeria. Turk J Haematol 2005; 22: 125-131.

Christopher A Egbe, Richard Omoregie and Otibhor Alex-Ighodalo

University of Benin Teaching Hospital, Benin City, Nigeria
Table 1. Effect of gender, age and CD4 count on the prevalence
of cryptococcosis among HIV patients on HAART

Characteristics             No. tested   No. positive (%)    OR

Gender
Male                           156           13 (8.3)       0.714
Female                         177          20 (11.3)       1.401

Age (years)
21-30                           57           8 (14.0)
31-40                          103          13 (12.6)
41-50                          116            8(6.9)
51-60                           57            4(7.0)

CD4 count (cell/[micro]L)
< 200                          121          22 (18.2)       4.06
[greater than or               212           11 (5.2)       0.246
  equal to] 200

Characteristics               95% CI        P

Gender
Male                        0.342,1.487   0.471
Female                      0.672,2.920

Age (years)
21-30                                     0.302
31-40
41-50
51-60

CD4 count (cell/[micro]L)
< 200                       1.893,8.708   0.0003
[greater than or            0.115,0.528
  equal to] 200

OR = odds ratio; CI = confidence interval.
COPYRIGHT 2015 New Zealand Institute of Medical Laboratory Science
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:ORIGINAL ARTICLE
Author:Egbe, Christopher A.; Omoregie, Richard; Alex-Ighodalo, Otibhor
Publication:New Zealand Journal of Medical Laboratory Science
Article Type:Report
Geographic Code:6NIGR
Date:Apr 1, 2015
Words:1706
Previous Article:Hodgkin and Reed-Sternberg cells in bone marrow aspirations of a patient with advanced classical Hodgkin lymphoma.
Next Article:Comparison of BD Phoenix nitrocefin, a cefinase disk test, and Phoenix MIC for the detection of hyper [beta]-lactamase in Staphylococcus...
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters